Associated Papers
Mutational status of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): molecular analysis should be performed for NIFTPs with nuclear score 3.
Sako A et al.
Journal of Pathology and Translational Medicine, 2026
Outside canonical BRAF p.V600E Box: 7 novel BRAF gene fusions in BRAF p.V600E WT papillary thyroid carcinoma.
McGrath N et al.
Virchows Archiv : an International Journal of Pathology, 2026
Malignant struma ovarii: Advances in molecular pathogenesis, classification, diagnosis and treatment.
Lin W et al.
Histopathology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The molecular profile of ovarian struma ovarii.
Calejero I et al.
Human Pathology, 2026
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.
Sini C et al.
European Journal of Cancer (oxford, England : 1990), 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Malignancy Risk, Molecular Mutations, and Surgical Outcomes of Thyroid Nodules Classified as Atypia of Undetermined Significance in the Bethesda System: A Comprehensive Analysis.
Bourque C et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology, 2026
Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.
Tessler I et al.
Clinical Endocrinology, 2026
Review of Genomic Drivers of Thyroid Cancer and Their Clinical Implications.
Mohammed S et al.
Genes, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Harnessing liquid biopsy to unveil RAS-MEK pathway somatic pathogenic variants in extracranial arterio-venous malformations.
Bhatia KD et al.
Communications Medicine, 2025
Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma.
Chen YF et al.
American Journal of Clinical Pathology, 2025
Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.
Lescuyer G et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
Nguyen MK et al.
The Oncologist, 2025
Undifferentiated Melanoma: A Clinicopathologic and Gene Expression Analysis Study With Identification of HMGA2 as a Diagnostic Marker.
Fischer GM et al.
The American Journal of Surgical Pathology, 2025
Exploring the Genetic Landscape of Primary Marginal Zone Lymphoma of the Urinary Bladder.
Balestri I et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.
Lu K et al.
Npj Precision Oncology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma.
Zambelli V et al.
Endocrine Pathology, 2025
Malignant struma ovarii: clinicopathological and molecular features in a series of nine cases.
Yang X et al.
Virchows Archiv : an International Journal of Pathology, 2025
Primary sellar glomus tumor with BRAF K601E mutation: an aggressive tumor of uncertain malignant potential.
Mi B et al.
Brain Tumor Pathology, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.
Menzer C et al.
European Journal of Cancer (oxford, England : 1990), 2025
Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells.
Calafato G et al.
European Thyroid Journal, 2025
Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAFV600E: A Bi-Center Series of 52 Cases.
Alzumaili BA et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer.
Cirello V et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Invasive urothelial carcinoma with chordoid and myxoid features shows increased RAS/RAF pathway alterations.
Chan E et al.
Human Pathology, 2025
Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal Cancer.
Xie L et al.
Molecules (basel, Switzerland), 2025
[A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib].
Wang Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Clinicopathological and molecular characteristics of papillary thyroid carcinoma with BRAF V600E and TERT promoter co-mutations.
Liu R et al.
Pathology, Research and Practice, 2025
Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany.
Kropf-Sanchen C et al.
Esmo Open, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Mutational Profiling Detection in FNAC Samples of Different Types of Thyroid Neoplasms Using Targeted NGS.
Liang R et al.
Cancers, 2025